Als waarschuwing!
Het kan niet anders dan dit heeft zijn weerslag op Pharming.
Komt wel weer goed maar toch.
Prev Close: 139.50
Open: 139.66
Bid: 83.00 x 100
Ask: 83.75 x 300
1y Target Est: 168.59
Beta: 0.8
Next Earnings Date: N/A
Day's Range: 134.40 - 141.79
52wk Range: 79.70 - 172.98
Volume: 6,478,007
Avg Vol (3m): 1,957,110
Market Cap: 8.82B
P/E (ttm): 153.43
EPS (ttm): 0.90
Div & Yield: N/A (N/A)
People viewing SLXP also viewed:
ARNA ARIA VVUS PGNX REGN VRTX
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhEDGAR Online(Fri 6:03AM EST)
[$$] Salix Shares Plunge as Accounting Revision Showed Weak Drug Salesat The Wall Street Journal(Fri 12:42AM EST)
Salix Pharma Plunges 38% Late On Earnings Miss, Audit ProbeInvestor's Business Daily(Thu, Nov 6)
INVESTOR ALERT: Investigation of Salix Pharmaceuticals, Ltd. Announced by Glancy Binkow & Goldberg LLPBusiness Wire(Thu, Nov 6)
Salix Shares Plummet on Disclosure of Accounting Scandalat TheStreet(Thu, Nov 6)
SALIX SHAREHOLDER ALERT: Investor Rights Firm Johnson & Weaver, LLP Announces Investigation of Salix Pharmaceuticals Ltd.Business Wire(Thu, Nov 6)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Salix Pharmaceuticals, Ltd. - SLXPPR Newswire(Thu, Nov 6)
Salix reports 3Q loss, CFO resignsAP(Thu, Nov 6)
Salix Pharmaceuticals profit, revenue miss estimatesReuters(Thu, Nov 6)
Indexes Higher; El Pollo Loco Reports In Lineat Investor's Business Daily(Thu, Nov 6)
Salix Begins Search for New Finance Chief as Derbyshire Resignsat Bloomberg(Thu, Nov 6)
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Thu, Nov 6)
Salix Pharmaceuticals Reports 3Q2014 ResultsBusiness Wire(Thu, Nov 6)
4:03 pm Salix Pharma announced the appointment of Timothy Creech as acting CFO effectively immediately; Adam Derbyshire has resigned his position at the Company (shares halted)Briefing.com(Thu, Nov 6)
Salix Pharmaceuticals Appoints Acting Chief Financial OfficerBusiness Wire(Thu, Nov 6)
» More Headlines for SLXP
Add SLXP Headlines to My Yahoo!
+ My Yahoo!RSS
Press Releases
INVESTOR ALERT: Investigation of Salix Pharmaceuticals, Ltd. Announced by Glancy Binkow & Goldberg LLPBusiness Wire(Thu, Nov 6)
SALIX SHAREHOLDER ALERT: Investor Rights Firm Johnson & Weaver, LLP Announces Investigation of Salix Pharmaceuticals Ltd.Business Wire(Thu, Nov 6)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Salix Pharmaceuticals, Ltd. - SLXPPR Newswire(Thu, Nov 6)
» More Press Releases for SLXP
Salix Pharmaceuticals Ltd. (SLXP)
1d5d1m3m6m1y2y5ymax
customize chart
Select your broker
Compare Brokers
Comparison
Symbol % Chg Mkt Cap
SLXP Down 0.68% 8.82B
BAYRY 117.55B
GSK 107.58B
WCRX N/A
» More Competitors
Key Statistics
Forward P/E (1 yr): 19.79
P/S (ttm): 7.04
Ex-Dividend Date: N/A
» More Key Statistics
Analysts
Annual EPS Est (Dec-14) : 6.17
Quarterly EPS Est (Sep-14) : 1.55
Mean Recommendation*: 2.0
PEG Ratio (5 yr expected): 1.05
* (Strong Buy) 1.0 - 5.0 (Sell)
Analyst Opinion | Estimates
Ruud..